ITeos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 10, 2021 at 04:11 pm EST
Share
iTeos Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 104.27 million. Net income was USD 69.64 million compared to net loss of USD 10.68 million a year ago. Basic earnings per share from continuing operations was USD 1.98 compared to basic loss per share from continuing operations of USD 0.48 a year ago. Diluted earnings per share from continuing operations was USD 1.86 compared to diluted loss per share from continuing operations of USD 0.48 a year ago.
For the nine months, revenue was USD 104.27 million. Net income was USD 29.65 million compared to net loss of USD 23.13 million a year ago. Basic earnings per share from continuing operations was USD 0.84 compared to basic loss per share from continuing operations of USD 3.4 a year ago. Diluted earnings per share from continuing operations was USD 0.79 compared to diluted loss per share from continuing operations of USD 3.4 a year ago.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
ITEOS THERAPEUTICS, INC. 
